Jefferies Financial Group Comments on TScan Therapeutics, Inc.’s FY2022 Earnings (NASDAQ:TCRX)

TScan Therapeutics, Inc. (NASDAQ:TCRXGet Rating) – Equities research analysts at Jefferies Financial Group decreased their FY2022 earnings per share (EPS) estimates for TScan Therapeutics in a research report issued to clients and investors on Wednesday, November 9th. Jefferies Financial Group analyst C. Howerton now forecasts that the company will earn ($3.20) per share for the year, down from their prior forecast of ($2.66). The consensus estimate for TScan Therapeutics’ current full-year earnings is ($2.90) per share. Jefferies Financial Group also issued estimates for TScan Therapeutics’ FY2023 earnings at ($3.80) EPS and FY2024 earnings at ($2.90) EPS.

TScan Therapeutics Trading Up 7.8 %

Shares of TScan Therapeutics stock opened at $2.76 on Monday. TScan Therapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $9.30. The stock has a 50 day moving average of $2.98 and a 200 day moving average of $3.04.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC purchased a new position in TScan Therapeutics in the second quarter worth approximately $32,000. Prudential Financial Inc. purchased a new position in TScan Therapeutics in the third quarter worth approximately $34,000. Renaissance Technologies LLC purchased a new position in TScan Therapeutics in the first quarter worth approximately $37,000. Privium Fund Management UK Ltd purchased a new position in TScan Therapeutics in the third quarter worth approximately $48,000. Finally, LPL Financial LLC purchased a new position in shares of TScan Therapeutics during the second quarter worth $50,000. 35.81% of the stock is currently owned by hedge funds and other institutional investors.

About TScan Therapeutics

(Get Rating)

TScan Therapeutics, Inc, a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors.

Read More

Earnings History and Estimates for TScan Therapeutics (NASDAQ:TCRX)

Receive News & Ratings for TScan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TScan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.